The Number Needed to Vaccinate (NNV) against herpes zoster: a systematic review with meta-analysis

2021 ◽  
pp. 1-11
Author(s):  
George N. Okoli ◽  
Yahya Al-Yousif ◽  
Viraj K. Reddy ◽  
Mê-Linh Lê ◽  
Christine J. Neilson ◽  
...  
Keyword(s):  
Systematic Review ◽  
Herpes Zoster ◽  
Meta Analysis

scholarly journals Incidence of Herpes Zoster in HIV-Infected Patients Undergoing Antiretroviral Therapy: A Systematic Review and Meta-analysis

2021 ◽  
Vol 10 (11) ◽  
pp. 2300
Author(s):  
Han-Chang Ku ◽  
Yi-Tseng Tsai ◽  
Sriyani-Padmalatha Konara-Mudiyanselage ◽  
Yi-Lin Wu ◽  
Tsung Yu ◽  
...  
Keyword(s):  
Systematic Review ◽  
Herpes Zoster ◽  
Antiretroviral Therapy ◽  
Random Effects ◽  
Meta Analysis ◽  
People Living With Hiv ◽  
Funnel Plots ◽  
Sex With Men ◽  
Treat All ◽  
Living With Hiv

The incidence of herpes zoster (HZ) in patients infected with HIV is higher than that of the general population. However, the incidence of HZ in HIV patients receiving antiretroviral therapy (ART) remains unclear. This meta-analysis aimed to estimate the pooled incidence rate and risk factors for HZ in the post-ART era. We identified studies assessing the incidence of HZ in the post-ART era between 1 January 2000 and 28 February 2021, from four databases. Pooled risk ratios were calculated from 11 articles using a random-effects model. The heterogeneity of the included trials was evaluated by visually inspecting funnel plots, performing random-effects meta-regression and using I2 statistics. Of the 2111 studies screened, we identified 11 studies that were eligible for final inclusion in the systematic review and 8 studies that were eligible for a meta-analysis. The pooled incidence of HZ in the post-ART era (after the introduction of ART in 1997) was 2.30 (95% confidence interval (CI): 1.56–3.05) per 100 person years (PYs). The risks of incidence of HZ among people living with HIV included male sex (AOR: 4.35 (95% CI: 054–2.41)), men who have sex with men (AOR: 1.21 (95% CI: −0.76–1.13)), CD4 count < 200 cells/μL (AOR: 11.59 (95% CI: 0.53–4.38)) and not receiving ART (AOR: 2.89 (95% CI: −0.44–2.56)). The incidence of HZ is substantially lower among HIV infected patients receiving ART than those not receiving ART. Initiating ART immediately after diagnosis to treat all HIV-positive individuals is crucial to minimize the disease burden of HZ.

Herpes zoster as a marker of occult cancer: A systematic review and meta-analysis

2017 ◽  
Vol 74 (3) ◽  
pp. 215-235 ◽  
Author(s):  
S.A.J. Schmidt ◽  
A. Mor ◽  
H.C. Schønheyder ◽  
H.T. Sørensen ◽  
O.M. Dekkers ◽  
...  
Keyword(s):  
Systematic Review ◽  
Herpes Zoster ◽  
Meta Analysis ◽  
Occult Cancer

Biologics targeting type I interferons in SLE: A meta-analysis and systematic review of randomised controlled trials

Lupus ◽  
2020 ◽  
Vol 29 (14) ◽  
pp. 1845-1853
Author(s):  
Jeffery Wei Heng Koh ◽  
Cheng Han Ng ◽  
Sen Hee Tay
Keyword(s):  
Systematic Review ◽  
Herpes Zoster ◽  
Lupus Erythematosus ◽  
Viral Infections ◽  
Meta Analysis ◽  
Type I Interferons ◽  
Type I ◽  
Upper Respiratory Tract ◽  
Type I Ifn ◽  
Tract Infections

Objective The feed-forward loop of type I interferons (IFNs) production and subsequent immunopathology of systemic lupus erythematosus (SLE) has been hypothesised to be disrupted with inhibition of IFNα or type I IFN receptor subunit 1 (IFNAR). This systematic review and meta-analysis present the treatment efficacy and safety profile of monoclonal antibodies inhibiting IFNα or IFNAR. Methods A search was done using Medline, Embase and ClinicalTrials.gov for biologics targeting IFNα or IFNAR in SLE up to 3 Jan 2020. For the meta-analysis, analyses of binary variables were pooled using odds ratio (OR) with the Mantel Haenszel model. Results Anifrolumab 300 mg (n = 3 studies, 927 patients) was more effective than placebo in achieving SRI(4) (pooled OR = 1.91, CI 1.11-3.28, P = 0.02) and BICLA response (pooled OR = 2.25, CI 1.72-2.95, P < 0.00001). In SLE patients with high type I IFN gene signature, SRI(4) response was not achieved with anifrolumab in 2 studies, 450 patients. Treatment with IFNα and IFNAR inhibitors (n = 7 studies, 1590 patients) increased the risk of herpes zoster infection (pooled OR = 3.72, CI 1.88–7.39, P = 0.0002), upper respiratory tract infections, nasopharyngitis and bronchitis. Conclusion This meta-analysis substantiates IFNAR as a therapeutic target in SLE. Inhibition of type I IFNs predisposes to herpes zoster and other viral infections.

Risk of Stroke in Patients with Herpes Zoster: A Systematic Review and Meta-Analysis

2017 ◽  
Vol 26 (2) ◽  
pp. 301-307 ◽  
Author(s):  
Sheng-Ye Yang ◽  
Hong-Xing Li ◽  
Xin-Hao Yi ◽  
Guang-Liang Han ◽  
Qiang Zong ◽  
...  
Keyword(s):  
Systematic Review ◽  
Herpes Zoster ◽  
Meta Analysis

scholarly journals A systematic review and meta-analysis on herpes zoster and the risk of cardiac and cerebrovascular events

PLoS ONE ◽  
2017 ◽  
Vol 12 (7) ◽  
pp. e0181565 ◽  
Author(s):  
Nathaniel Erskine ◽  
Hoang Tran ◽  
Leonard Levin ◽  
Christine Ulbricht ◽  
Joyce Fingeroth ◽  
...  
Keyword(s):  
Systematic Review ◽  
Herpes Zoster ◽  
Meta Analysis ◽  
Cerebrovascular Events

scholarly journals Herpes zoster epidemiology in Latin America: A systematic review and meta-analysis

PLoS ONE ◽  
2021 ◽  
Vol 16 (8) ◽  
pp. e0255877
Author(s):  
Ariel Esteban Bardach ◽  
Carolina Palermo ◽  
Tomás Alconada ◽  
Macarena Sandoval ◽  
Darío Javier Balan ◽  
...  
Keyword(s):  
Systematic Review ◽  
Latin America ◽  
Herpes Zoster ◽  
Cumulative Incidence ◽  
Meta Analysis ◽  
Grey Literature ◽  
Case Fatality ◽  
Incidence Density ◽  
Bibliographic Databases ◽  
Hospitalization Rates

The epidemiology and burden of Herpes Zoster (HZ) are largely unknown, and there are no recent reviews summarizing the available evidence from the Latin America and Caribbean (LAC) region. We conducted a systematic review and meta-analysis to characterize the epidemiology and burden of HZ in LAC. Bibliographic databases and grey literature sources were consulted to find studies published (January 2000 –February 2020) with epidemiological endpoints: cumulative incidence and incidence density (HZ cases per 100,000 person-years), prevalence, case-fatality rates, HZ mortality, hospitalization rates, and rates of each HZ complication. Twenty-six studies were included with most studies coming from Brazil. No studies reported the incidence of HZ in the general population. In population at higher risk, the cumulative incidence ranged from 318–3,423 cases of HZ per 100,000 persons per year of follow-up. The incidence density was 6.4–36.5 cases per 1,000 person-years. Age was identified as a major risk factor towards HZ incidence which increase significantly in people >50 years of age. Hospitalization rates ranged from 3%–35.7%. The in-hospital HZ mortality rate ranged from 0%–36%. Overall, HZ mortality rates were found to be higher in females across all age groups and countries. The incidence of HZ complications (such as post-herpetic neuralgia, ophthalmic herpes zoster, and Ramsay Hunt syndrome) was higher in the immunosuppressed compared to the immunocompetent population. Acyclovir was the most frequently used therapy. Epidemiological data from Ministry of Health databases (Argentina, Brazil, Colombia, Chile y Mexico) and Institute for Health Metrics and Evaluation’s Global Burden of Disease project reported stable rates of hospitalizations and deaths over the last 10 years. High-risk groups for HZ impose a considerable burden in LAC. They could benefit from directed healthcare initiatives, including adult immunization, to prevent HZ occurrence and its complications.

Fire needling for herpes zoster: A systematic review and meta-analysis of randomized clinical trials

2019 ◽  
Vol 6 ◽  
pp. S150
Author(s):  
Nan-qi Zhao ◽  
Lily Lai ◽  
Xiao Wang ◽  
Li-yan Jia ◽  
Xun Li ◽  
...  
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Herpes Zoster ◽  
Randomized Clinical Trials ◽  
Meta Analysis

scholarly journals The risk of infections in adult patients with systemic lupus erythematosus: systematic review and meta-analysis

Rheumatology ◽  
2020 ◽  
Vol 60 (1) ◽  
pp. 60-72 ◽  
Author(s):  
José María Pego-Reigosa ◽  
Lindsay Nicholson ◽  
Nick Pooley ◽  
Sue Langham ◽  
Nina Embleton ◽  
...  
Keyword(s):  
Systematic Review ◽  
Herpes Zoster ◽  
General Population ◽  
Meta Analysis ◽  
Severe Infection ◽  
Infection Risk ◽  
Sensitivity Analyses ◽  
Healthy Controls ◽  
Increased Risk ◽  
The Impact

Abstract Objectives We conducted a systematic review and meta-analysis to determine the magnitude of infection risk in patients with SLE and evaluate the effect of general and SLE-related factors on infection risk. Methods We searched MEDLINE and Embase from inception to July 2018, screening for observational studies that evaluated infection risk in patients with SLE compared with the general population/healthy controls. Outcomes of interest included overall severe infection, herpes zoster infection/reactivation, opportunistic infections, pneumonia and tuberculosis. Random-effects models were used to calculate pooled risk ratios (RRs) for each type of infection. Sensitivity analysis assessed the impact of removing studies with high risk of bias. Results Eleven retrospective or prospective cohort studies were included in the meta-analysis: overall severe infection (n = 4), pneumonia (n = 6), tuberculosis (n = 3) and herpes zoster (n = 2). Pooled RRs for overall severe infection significantly increased for patients with SLE compared with the general population/healthy controls [RR 2.96 (95% CI 1.28, 6.83)]. Pooled RRs for pneumonia, herpes zoster and tuberculosis showed significantly increased risk compared with the general population/healthy controls [RR 2.58 (1.80, 3.70), 2.50 (2.36, 2.65) and 6.11 (3.61, 10.33), respectively]. Heterogeneity and evidence of publication bias were present for all analyses, except herpes zoster. Sensitivity analyses confirmed robustness of the results. Conclusion Patients with SLE have significantly higher risk of infection compared with the general population/healthy controls. Efforts to strengthen strategies aimed at preventing infections in SLE are needed. Protocol registration PROSPERO number: CRD42018109425.

Sign in / Sign up

Export Citation Format

Share Document